← Back to Clinical Trials
Recruiting NCT07776756

NCT07776756 Enamel Matrix Derivative and Xenograft for Mandibular Molar Furcation Defects

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07776756
Status Recruiting
Phase
Sponsor University of Medicine and Pharmacy at Ho Chi Minh City
Condition Class II Furcation Defect
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2026-06-29
Primary Completion 2027-09-29

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Periodontal Regenerative Surgery With Xenograft and Enamel Matrix DerivativePeriodontal Regenerative Surgery With Xenograft and Collagen Membrane

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2026-06-29 with a primary completion date of 2027-09-29.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled clinical trial aims to compare two regenerative surgical approaches for the treatment of mandibular molar Class II furcation defects in patients with periodontitis. Eligible furcation defects will be randomly assigned to receive either xenograft bone combined with enamel matrix derivative (EMD) or xenograft bone combined with a collagen membrane. Both approaches are used to support periodontal tissue regeneration. Participants will be followed for approximately 7 months. The study will evaluate postoperative pain and patient-reported satisfaction, periodontal clinical parameters, changes in furcation defect volume and relative bone density on cone-beam computed tomography (CBCT), and changes in gingival crevicular fluid TWEAK levels. Clinical and radiographic outcomes will be assessed before surgery and during follow-up, including at 3 and 6 months after surgery. The study is intended to determine whether xenograft bone combined with EMD provides clinical, radiographic, biological, and patient-reported outcomes comparable or superior to xenograft bone combined with a collagen membrane in the regenerative treatment of mandibular molar Class II furcation defects.

Eligibility Criteria

Inclusion Criteria: * Age 18 years or older. * Full-mouth plaque score (FMPS) ≤ 20%. * Full-mouth bleeding score (FMBS) ≤ 20%. * Willingness to participate in the study and provide informed consent. * Mandibular first and/or second molar with a buccal Class II furcation defect classified as subgroup A2 or B2. * Probing pocket depth (PPD) ≥ 5 mm at the eligible furcation site. * Keratinized gingival height ≥ 2 mm at the eligible site. * No gingival recession extending apically beyond the buccal furcation roof; the furcation entrance must not be clinically exposed above the gingival margin. Exclusion Criteria: * Systemic diseases or conditions that may affect periodontal treatment outcomes, including uncontrolled diabetes mellitus, heart disease requiring anticoagulant therapy, hematologic disorders, or immunodeficiency. * Pregnancy or breastfeeding. * Untreated endodontic pathology involving the study tooth. * Class III furcation involvement according to the Hamp classification. * Untreated occlusal trauma involving the study tooth. * Grade II tooth mobility that has not been stabilized by splinting, or Grade III tooth mobility according to the Miller classification. * Defective restorations at the surgical site, including overhanging, bulky, or poorly adapted restorations.

Frequently Asked Questions

Who can join the NCT07776756 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Class II Furcation Defect. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07776756 currently recruiting?

Yes, NCT07776756 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Medicine and Pharmacy at Ho Chi Minh City to inquire about joining.

Where is the NCT07776756 trial being conducted?

This trial is being conducted at Ho Chi Minh City, Vietnam.

Who is sponsoring the NCT07776756 clinical trial?

NCT07776756 is sponsored by University of Medicine and Pharmacy at Ho Chi Minh City. The trial plans to enroll 24 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology